Polyclonal Antibody to Inhibitor Of Apoptosis Protein, X-Linked (XIAP)
| Code | Size | Price |
|---|
| PAC606Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAC606Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAC606Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAC606Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
BIRC4; API3; ILP1; MIHA; XLP2; Baculoviral IAP Repeat-Containing 4; E3 ubiquitin-protein ligase XIAP; IAP-like; Inhibitor of apoptosis protein 3; Inhibitor Of Apoptosis Protein, X-Linked
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
X-linked Inhibitor Of Apoptosis Protein
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-3ug/mL;<br/>Immunohistochemistry: 2-30ug/mL;<br/>Immunocytochemistry: 2-30ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant X-Linked Inhibitor Of Apoptosis Protein (XIAP) | RPC606Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||